145 related articles for article (PubMed ID: 27324368)
1. Evaluation of [
Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
[TBL] [Abstract][Full Text] [Related]
2. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH
Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010
[TBL] [Abstract][Full Text] [Related]
3. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
[TBL] [Abstract][Full Text] [Related]
6. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
7. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
[TBL] [Abstract][Full Text] [Related]
8. The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):257-63. PubMed ID: 15791434
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.
Shinomiya A; Kawai N; Okada M; Miyake K; Nakamura T; Kushida Y; Haba R; Kudomi N; Yamamoto Y; Tokuda M; Tamiya T
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):175-85. PubMed ID: 23229746
[TBL] [Abstract][Full Text] [Related]
10. 3'-Deoxy-3'-[
Schelhaas S; Heinzmann K; Honess DJ; Smith DM; Keen H; Heskamp S; Witney TH; Besret L; Doblas S; Griffiths JR; Aboagye EO; Jacobs AH
Mol Imaging Biol; 2018 Apr; 20(2):194-199. PubMed ID: 28971330
[TBL] [Abstract][Full Text] [Related]
11. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
[TBL] [Abstract][Full Text] [Related]
12. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
[TBL] [Abstract][Full Text] [Related]
13. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
14. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
15. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
[TBL] [Abstract][Full Text] [Related]
16. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
18. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
19. 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.
Ashek A; Spruijt OA; Harms HJ; Lammertsma AA; Cupitt J; Dubois O; Wharton J; Dabral S; Pullamsetti SS; Huisman MC; Frings V; Boellaard R; de Man FS; Botros L; Jansen S; Vonk Noordegraaf A; Wilkins MR; Bogaard HJ; Zhao L
Circ Cardiovasc Imaging; 2018 Aug; 11(8):e007402. PubMed ID: 30354494
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Perumal M; Stronach EA; Gabra H; Aboagye EO
Mol Imaging Biol; 2012 Dec; 14(6):753-61. PubMed ID: 22484552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
